Payment overview · 2025
General Payments
$1,876.63
76 reported records · 22 companies
Healthcare provider profile · identity verified
Yan Bai, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GLENDALE, CA · NPI 1558612804
Verified facts
What the public records show
CMS Open Payments records show Yan Bai, NP received $1,876.63 in general payments during 2025 across 76 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Loreev Xr, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta, Tyrvaya, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Zenpep by this doctor in 2024.
Almatica Pharma LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOREEV XR as an associated drug or biological on 9621 records involving 4446 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Loreev Xr by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
Oyster Point Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYRVAYA as an associated drug or biological on 8925 records involving 5041 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Tyrvaya by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $291.92 | 15.6% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $202.18 | 10.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $188.53 | 10.1% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.25 | 8.2% | 7 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $124.41 | 6.6% | 5 | 2025 |
| Oyster Point Pharma, Inc. | Unresolved — no canonical attribution shown | $107.89 | 5.8% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $103.02 | 5.5% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $99.69 | 5.3% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $82.24 | 4.4% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $78.30 | 4.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $71.75 | 3.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.00 | 2.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.60 | 2.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.29 | 2.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.93 | 2.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.46 | 2.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.04 | 1.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $28.35 | 1.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.00 | 1.5% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $24.80 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.86 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.12 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,876.63 | 76 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $291.92 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $202.18 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $141.98 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $131.63 | 6 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $124.41 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $113.18 | 5 | 2025 |
Source payment records
|
|||||
| TYRVAYA Normalized: tyrvaya |
Drug | Oyster Point Pharma, Inc. | $107.89 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $103.02 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $84.42 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $82.24 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $78.30 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $70.30 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $64.88 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $56.90 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.00 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.60 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $41.46 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.04 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $28.35 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 30 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 129 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 54 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 86 | exact normalized | Medicare Part D |
| LOREEV XR loreev xr |
2025 | Loreev Xr | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 | exact normalized | Medicare Part D |
| TYRVAYA tyrvaya |
2025 | Tyrvaya | 2024 | 23 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
30 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
86 | 36 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
33 | 16 |
| Almatica Pharma LLC Exact reporting entity; no affiliate inference |
2025 | LOREEV XR open payments reported associated product |
CMS Open Payments — General Payments 9621 supporting records · 4446 recipient NPIs · example record 1209929018 |
Loreev Xr · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
25 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
129 | 49 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
54 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | 18 |
| Oyster Point Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | TYRVAYA open payments reported associated product |
CMS Open Payments — General Payments 8925 supporting records · 5041 recipient NPIs · example record 1238388111 |
Tyrvaya · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 247 |
| Amlodipine Besylate | Amlodipine Besylate | 497 | 201 |
| Losartan Potassium | Losartan Potassium | 366 | 146 |
| Vascepa | Icosapent Ethyl | 285 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 267 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 110 |
| Metformin Hcl | Metformin Hcl | 242 | 103 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 160 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 59 |
| Omeprazole | Omeprazole | 142 | 71 |
| Farxiga | Dapagliflozin Propanediol | 129 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 120 | 51 |
| Icosapent Ethyl | Icosapent Ethyl | 101 | 54 |
| Donepezil Hcl | Donepezil Hcl | 95 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 94 | 33 |
| Alendronate Sodium | Alendronate Sodium | 92 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 41 |
| Linzess | Linaclotide | 86 | 36 |
| Montelukast Sodium | Montelukast Sodium | 83 | 44 |
| Gabapentin | Gabapentin | 78 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 75 | 44 |
| Finasteride | Finasteride | 74 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 29 |
| Jardiance | Empagliflozin | 67 | 29 |
| Diclofenac Epolamine | Diclofenac Epolamine | 65 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 32 |
| Carvedilol | Carvedilol | 58 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 36 |
| Fenofibrate | Fenofibrate | 56 | 26 |
| Mirtazapine | Mirtazapine | 56 | 20 |
| Celecoxib | Celecoxib | 54 | 39 |
| Kerendia | Finerenone | 54 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 41 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 21 |
| Restasis | Cyclosporine | 44 | 20 |
| Amoxicillin | Amoxicillin | 42 | 32 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | 18 |
| Allopurinol | Allopurinol | 41 | 23 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 40 | 14 |
| Ezetimibe | Ezetimibe | 39 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 38 | 20 |
| Ozempic | Semaglutide | 38 | 17 |
| Azithromycin | Azithromycin | 37 | 35 |
| Trazodone Hcl | Trazodone Hcl | 36 | 18 |
| Fluocinonide | Fluocinonide | 35 | 24 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 34 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | 11 |
| Simvastatin | Simvastatin | 34 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 14 |
| Zenpep | Lipase/Protease/Amylase | 33 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 16 |
| Eliquis | Apixaban | 31 | 16 |
| Creon | Lipase/Protease/Amylase | 30 | 18 |
| Famotidine | Famotidine | 30 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | 13 |
| Azelastine Hcl | Azelastine Hcl | 29 | 16 |
| Gemtesa | Vibegron | 29 | 14 |
| Ketoconazole | Ketoconazole | 29 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | 14 |
| Rybelsus | Semaglutide | 29 | 18 |
| Glimepiride | Glimepiride | 27 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | 14 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 26 | suppressed |
| Prolia | Denosumab | 25 | 18 |
| Ranolazine Er | Ranolazine | 25 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 15 |
| Cyclosporine | Cyclosporine | 24 | 19 |
| Dutasteride | Dutasteride | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 19 |
| Tyrvaya | Varenicline Tartrate | 23 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | 13 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 14 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | 17 |
| Mupirocin | Mupirocin | 20 | 18 |
| Licart | Diclofenac Epolamine | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Ursodiol | Ursodiol | 19 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 15 |
| Valsartan | Valsartan | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | 13 |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | 12 |
| Loreev Xr | Lorazepam | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,876.63 · 76 records | Bayer Healthcare Pharmaceuticals Inc. | BREZTRI, CREON, Cologuard Collection Kit, FARXIGA, GEMTESA, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, LOREEV XR, MOUNJARO, OTEZLA, Ozempic, PANCREAZE, PAXLOVID, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TYRVAYA, XIFAXAN, ZENPEP, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error